Literature DB >> 18299524

The history of progressive muscular atrophy: syndrome or disease?

Jeldican Visser1, J M B Vianney de Jong, Marianne de Visser.   

Abstract

Since its first description more than a century ago, there has been much debate about the diagnostic entity progressive muscular atrophy (PMA). Initially, PMA included all forms of progressive amyotrophy. With the identification of several myogenic and neurogenic diseases and the recognition of amyotrophic lateral sclerosis (ALS), PMA was deemed to disappear as a nosologic entity at the end of the 19th century. In the last century, various other lower motor neuron syndromes were distinguished which may previously have been designated as cases of PMA. In contrast, several observations provided evidence that PMA can be linked both clinically and pathologically to ALS. Therefore, PMA should be considered as a syndromal subtype within a clinical spectrum of motor neuron diseases.

Entities:  

Mesh:

Year:  2008        PMID: 18299524     DOI: 10.1212/01.wnl.0000302187.20239.93

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  8 in total

1.  White matter pathology in ALS and lower motor neuron ALS variants: a diffusion tensor imaging study using tract-based spatial statistics.

Authors:  Johannes Prudlo; Charlotte Bißbort; Aenne Glass; Annette Grossmann; Karlheinz Hauenstein; Reiner Benecke; Stefan J Teipel
Journal:  J Neurol       Date:  2012-02-21       Impact factor: 4.849

2.  Lockhart Clarke's contribution to the description of amyotrophic lateral sclerosis.

Authors:  Martin R Turner; Michael Swash; George C Ebers
Journal:  Brain       Date:  2010-06-24       Impact factor: 13.501

Review 3.  Controversies and priorities in amyotrophic lateral sclerosis.

Authors:  Martin R Turner; Orla Hardiman; Michael Benatar; Benjamin R Brooks; Adriano Chio; Mamede de Carvalho; Paul G Ince; Cindy Lin; Robert G Miller; Hiroshi Mitsumoto; Garth Nicholson; John Ravits; Pamela J Shaw; Michael Swash; Kevin Talbot; Bryan J Traynor; Leonard H Van den Berg; Jan H Veldink; Steve Vucic; Matthew C Kiernan
Journal:  Lancet Neurol       Date:  2013-03       Impact factor: 44.182

4.  Genetic and constitutional factors are major contributors to substantia nigra hyperechogenicity.

Authors:  Juan F Vázquez-Costa; José I Tembl; Victoria Fornés-Ferrer; Fernando Cardona; Lluis Morales-Caba; Gerardo Fortea; Jordi Pérez-Tur; Teresa Sevilla
Journal:  Sci Rep       Date:  2017-08-02       Impact factor: 4.379

5.  Role of the nigrosome 1 absence as a biomarker in amyotrophic lateral sclerosis.

Authors:  María Isabel Moreno-Gambín; José I Tembl; Miguel Mazón; Antonio José Cañada-Martínez; Luis Martí-Bonmatí; Teresa Sevilla; Juan F Vázquez-Costa
Journal:  J Neurol       Date:  2021-08-11       Impact factor: 4.849

6.  Latent cluster analysis of ALS phenotypes identifies prognostically differing groups.

Authors:  Jeban Ganesalingam; Daniel Stahl; Lokesh Wijesekera; Clare Galtrey; Christopher E Shaw; P Nigel Leigh; Ammar Al-Chalabi
Journal:  PLoS One       Date:  2009-09-22       Impact factor: 3.240

7.  Natural history and clinical features of the flail arm and flail leg ALS variants.

Authors:  L C Wijesekera; S Mathers; P Talman; C Galtrey; M H Parkinson; J Ganesalingam; E Willey; M A Ampong; C M Ellis; C E Shaw; A Al-Chalabi; P N Leigh
Journal:  Neurology       Date:  2009-03-24       Impact factor: 9.910

8.  Klinefelter's syndrome associated with progressive muscular atrophy simulating Kennedy's disease.

Authors:  Pedro Enrique Jiménez Caballero
Journal:  Ann Indian Acad Neurol       Date:  2012-07       Impact factor: 1.383

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.